Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

(2016) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Brodalumab: First Global Approval

(2016) Sarah L. Greig   DRUGS

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study

(2016) Akihiko Asahina et al.   JOURNAL OF DERMATOLOGY

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

(2016) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study

(2016) F. Valenzuela et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis

(2016) Fawziah Marra et al.   Open Forum Infectious Diseases

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

(2015) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

(2015) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors

(2015) J. Segan et al.   INTERNAL MEDICINE JOURNAL

Efficacy comparison of ustekinumab between anti-tumor necrosis factor-αdrug-naïve and anti-tumor necrosis factor-αdrug-resistant Japanese psoriasis cases

(2015) Naomi Takahashi et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Psoriasis

(2015) Wolf-Henning Boehncke et al.   LANCET

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs

(2015) Dimitrios A. Pappas et al.   ARTHRITIS CARE & RESEARCH

Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database

(2015) K. Kubota et al.   BMJ Open

Systemic Therapy for Psoriasis and the Risk of Herpes Zoster

(2015) Guy Shalom et al.   JAMA Dermatology

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

(2015) Robert E. Kalb et al.   JAMA Dermatology

Psoriatic arthritis treatment and the risk of herpes zoster

(2014) D Zisman et al.   ANNALS OF THE RHEUMATIC DISEASES

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Risk of herpes zoster in psoriatic patients undergoing biologic treatment

(2014) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study

(2014) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

(2014) Mark G. Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Satisfaction with treatment among patients with psoriasis: a web-based survey study

(2013) O.D. van Cranenburgh et al.   BRITISH JOURNAL OF DERMATOLOGY

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice

(2013) K. Callis Duffin et al.   BRITISH JOURNAL OF DERMATOLOGY

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis

(2013) Helene Che et al.   JOINT BONE SPINE

Japanese guidance for use of biologics for psoriasis (the 2013 version)

(2013) Mamitaro Ohtsuki et al.   JOURNAL OF DERMATOLOGY

The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis

(2013) Emmilia A. Dowlatshahi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions

(2013) L. Adelzadeh et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriasis and cardiovascular risk factors: A case-control study on inpatients comparing psoriasis to dermatitis

(2011) Jonathan Shapiro et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs

(2011) J. Dreiher et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis

(2010) D. H. Solomon et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma

(2010) Hideshi TORII et al.   JOURNAL OF DERMATOLOGY

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

(2009) N. N. Mehta et al.   EUROPEAN HEART JOURNAL

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis and diabetes: a population-based cross-sectional study

(2008) AD Cohen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY